Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Jonathan E. Kolitz"'
Autor:
Robert K. Stuart, Grerk Sutamtewagul, Ann-Kathrin Eisfeld, Ravi Vij, Krzysztof Mrózek, Jessica Kohlschmidt, Mohan Thakuri, Richard Stone, William Blum, Wendy Stock, Andrew J. Carroll, Jonathan E. Kolitz, Richard A. Larson, Guido Marcucci, Eunice S. Wang, Clara D. Bloomfield, Jun Yin, John C. Byrd, Alison Walker, Sawyer B. Jacobson
Publikováno v:
Blood Adv
Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide dire
Autor:
Dale L. Bixby, Jeffrey E. Lancet, Robert K. Stuart, Scott R. Solomon, Laura F. Newell, Ellen K. Ritchie, Donna E. Hogge, Geoffrey L. Uy, Daniel H. Ryan, Stephen A. Strickland, Gary J. Schiller, Stefan Faderl, Tara L. Lin, Jorge E. Cortes, Jonathan E. Kolitz, Matthew J Wieduwilt
Publikováno v:
The Lancet Haematology. 8:e481-e491
Summary Background Daunorubicin and cytarabine are used as standard induction chemotherapy for patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. Prim
Autor:
Jessica Kohlschmidt, Richard Stone, Dimitrios Papaioannou, Clara D. Bloomfield, Adrienne M. Dorrance, Marius Bill, Bayard L. Powell, Andrew J. Carroll, Deedra Nicolet, Jonathan E. Kolitz, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Zachary Brannan, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Kellie J. Archer, Christopher J. Walker
Publikováno v:
Haematologica
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understandi
Autor:
Jonathan E. Kolitz, Susan M. Christner, Michaela Liedtke, Richard Stone, Geoffrey L. Uy, Meir Wetzler, Jan H. Beumer, Lionel D. Lewis, Jun Yin, Matthew J Wieduwilt, Wendy Stock, Elizabeth Storrick, Richard A. Larson, Steven M. Devine, Ryan J. Mattison, Bayard L. Powell
Publikováno v:
Blood Advances
Key Points Dasatinib and dexamethasone induction then allogeneic hematopoietic cell transplantation was feasible and effective for untreated Ph+ ALL.Treatment failure was associated with BCR-ABL1 T315I mutation, the p210 BCR-ABL1 isoform, or isolated
Autor:
Deedra Nicolet, John C. Byrd, Sumithira Vasu, Klaus H. Metzeler, Joseph O. Moore, Krzysztof Mrózek, Heiko Becker, Jessica Kohlschmidt, Dimitrios Papaioannou, Andrew J. Carroll, Clara D. Bloomfield, Gail J. Roboz, Lisa J. Sterling, Maria R. Baer, Bayard L. Powell, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Richard Stone
Publikováno v:
Blood Advances. 2:1645-1650
The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 1
Autor:
Sophia E. Maharry, Jonathan E. Kolitz, Jessica Kohlschmidt, Richard Stone, Eunice S. Wang, Bayard L. Powell, James S. Blachly, Clara D. Bloomfield, Christopher J. Walker, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Andrew J. Carroll, Deedra Nicolet, John C. Byrd, Shelley Orwick, Albert de la Chapelle
Publikováno v:
Leukemia
Thus far, only 5-15% of AML patients aged ≥60 years are cured with chemotherapy. Identification of patients who are less (more) likely to respond to standard chemotherapy might enable early risk stratification toward alternative treatment regimens.
Autor:
Eunice S. Wang, Deedra Nicolet, Andrew J. Carroll, A-K Eisfeld, Clara D. Bloomfield, Christopher J. Walker, Shelley Orwick, Jonathan E. Kolitz, Richard Stone, James S. Blachly, A de la Chapelle, John C. Byrd, Karl Kroll, Jessica Kohlschmidt, Krzysztof Mrózek, Bayard L. Powell
Publikováno v:
Leukemia
Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific
Autor:
Jeffrey E. Lancet, Daniel H. Ryan, Michael Chiarella, Robert K. Stuart, Geoffrey L. Uy, Jorge E. Cortes, Dale L. Bixby, Kamalika Banerjee, Richard Stone, Antje Hoering, Matthew J. Wieduwilt, Arthur C. Louie, Bruno C. Medeiros, Tara L. Lin, Donna E. Hogge, Laura F. Newell, Jonathan E. Kolitz, Scott R. Solomon, Ellen K. Ritchie, Stephen A. Strickland, Gary J. Schiller
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 26
Journal of Clinical Oncology
Journal of Clinical Oncology
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f572e52303fbaff3d4b8389b847403
https://escholarship.org/uc/item/74b073ht
https://escholarship.org/uc/item/74b073ht
Autor:
Kristen E. Stevenson, Julie D. Asch, Jonathan E. Kolitz, Karen K. Ballen, David P. Steensma, Julia Foster, Martha Wadleigh, Daniel J. DeAngelo, Eyal C. Attar, Amir T. Fathi, Ilene Galinsky, Christine Connolly, Craig Devoe, Philip C. Amrein, Donna Neuberg, Richard Stone
Publikováno v:
Cancer. 122:2379-2388
BACKGROUND Outcomes among older patients with acute lymphoblastic leukemia remain poor. This study sought to determine the efficacy of an intensified, multi-agent approach derived from a Dana-Farber consortium trial in younger adults for patients old
Autor:
Donna E. Hogge, Daniel H. Ryan, Jorge E. Cortes, Jonathan E. Kolitz, Robert J. Ryan, Stefan Faderl, Tara L. Lin, Scott R. Solomon, Matthew J. Wieduwilt, Ellen K. Ritchie, Stephen A. Strickland, Gary J. Schiller
Publikováno v:
Blood. 134:1316-1316
Introduction: Patients (pts) with newly diagnosed, secondary AML (sAML) may have previously received hypomethylating agent (HMA) therapy for an antecedent hematologic malignancy (eg, myelodysplastic syndrome [MDS]). Outcomes for pts with MDS who prog